Winter Special Sale Limited Time 60% Discount Offer - Ends in 0d 00h 00m 00s - Coupon code: 2493360325

Good News !!! RAC-US Regulatory Affairs Certification (RAC) US is now Stable and With Pass Result

RAC-US Practice Exam Questions and Answers

Regulatory Affairs Certification (RAC) US

Last Update 8 hours ago
Total Questions : 100

Regulatory Affairs Certification (RAC) US is stable now with all latest exam questions are added 8 hours ago. Incorporating RAC-US practice exam questions into your study plan is more than just a preparation strategy.

RAC-US exam questions often include scenarios and problem-solving exercises that mirror real-world challenges. Working through RAC-US dumps allows you to practice pacing yourself, ensuring that you can complete all Regulatory Affairs Certification (RAC) US practice test within the allotted time frame.

RAC-US PDF

RAC-US PDF (Printable)
$83.6
$209

RAC-US Testing Engine

RAC-US PDF (Printable)
$119.6
$299

RAC-US PDF + Testing Engine

RAC-US PDF (Printable)
$139.6
$349
Question # 1

According to WHO, what are the temperature and humidity conditions for a Zone IVb long-term stability study?

Options:

A.  

25: C and 60% RH

B.  

30° C and 35% RH

C.  

30c C and 65% RH

D.  

30: C and 75% RH

Discussion 0
Question # 2

Which of the following is the PRIMARY purpose of an audit report?

Options:

A.  

To carry out a complete review of product applications

B.  

To define how to prepare new product submissions

C.  

To document compliance history

D.  

To train sales representatives

Discussion 0
Question # 3

Company X encounters challenges in the global life cycle management of its medical devices. Which of the following Is MOST appropriate for improving product life cycle management?

Options:

A.  

Utilize the STED template to complete global requirements.

B.  

Initiate a global submission process after all submission data are finalized.

C.  

Identify countries where special requirements exist during the product development phase.

D.  

Plan regulatory approval update meetings with senior management and stakeholders.

Discussion 0
Question # 4

During routine surveillance, a regulatory authority sent a company the following communication: "Hepatotoxicity and suicidal behavior were identified as potential safety issues for the company's product. The regulatory authority is evaluating these issues to determine the need for any regulatory action." Which action would be the most appropriate FIRST step for the company to take?

Options:

A.  

Contact the regulatory authority to argue that its conclusions are wrong.

B.  

Contact the regulatory authority to discuss its findings.

C.  

Repeat the Hepatotoxicity tests and send the results to the regulatory authority.

D.  

Wait for the regulatory authority's final publication on its findings.

Discussion 0
Question # 5

A drug product presents degradation during the manufacturing process. In addition to the amount, what information should be provided FIRST in order to use API overage?

Options:

A.  

Specification

B.  

Formulation

C.  

Property

D.  

Justification

Discussion 0
Question # 6

A company is developing a novel drug to combat AIDS. The preliminary results are very promising and include instances of complete remission. The company has been granted patents in multiple countries for the drug. The regulatory affairs professional is asked to prepare a brief report concerning potential problems for marketing of the product worldwide. Which of the following is the MOST important consideration to discuss?

Options:

A.  

Doha Declaration in the TRIPS Agreement

B.  

The stability of the drug in all zone conditions

C.  

The time frame in which the patent will expire

D.  

International import and export regulations

Discussion 0
Question # 7

During new drug development, a new impurity in the drug substance is detected at a level of 0.12%. The intended maximum daily dose Is less than 2 g/day, and the drug Is known generally not to be toxic.

What should be done in response to identifying the impurity?

Options:

A.  

Perform either an identification study or a non-clinical qualification study.

B.  

Perform both identification and non-clinical qualification studies concurrently.

C.  

Perform an identification study, wait until the result is available, and then consider performing a non-clinical qualification study.

D.  

Perform a non-clinical qualification study, wait until the result is available, and then consider performing an identification study.

Discussion 0
Question # 8

A company is developing a new medical device. During which initial stage is it MOST appropriate (or a regulatory affairs professional to become involved?

Options:

A.  

Concept development and validation

B.  

Concept development and early technical design

C.  

Early technical design and product release

D.  

Product release and validation

Discussion 0
Question # 9

GHTF recommends that the medical device manufacturer define the scope of the clinical evaluation based on which of the following?

Options:

A.  

Instructions for use

B.  

Risk analysis

C.  

Product literature

D.  

Essential principles

Discussion 0
Question # 10

A company is developing a new medical device using innovative technology. Which of the following is MOST critical in working with regulatory authorities?

Options:

A.  

Documented agreement

B.  

Frequent communication

C.  

Early collaboration

D.  

Follow-up meeting after submission

Discussion 0
Get RAC-US dumps and pass your exam in 24 hours!

Free Exams Sample Questions